Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775756 | 0.91 | KMT2A (0.53) | ALDH1A1KMT2ATSHRF10PRSS1 | |
| SCHEMBL15614426 | 0.84 | KMT2A (0.47) | ALDH1A1KMT2AF10PRSS1PRSS2 | |
| SCHEMBL15119351 | 0.84 | CYP2C19 (0.58) | ALDH1A1KMT2AF10PRSS1PRSS2 | |
| SCHEMBL9228822 | 0.81 | LMNA (0.56) | ALDH1A1KMT2ATSHRLMNAHTT | |
| SCHEMBL20202315 | 0.81 | ALDH1A1 (0.66) | ALDH1A1KMT2ATSHRLMNAHTT | |
| SCHEMBL14349167 | 0.81 | TSHR (0.52) | ALDH1A1KMT2ATSHRF10PRSS1 | |
| SCHEMBL16775760 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KMT2AF10PRSS1PRSS2 | |
| SCHEMBL8548241 | 0.80 | KMT2A (0.78) | ALDH1A1KMT2ATSHRLMNAHTT | |
| SCHEMBL20647114 | 0.80 | KMT2A (0.48) | ALDH1A1KMT2ATSHRF10PRSS1 | |
| SCHEMBL18085906 | 0.80 | ALDH1A1 (0.68) | ALDH1A1F10PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010135014-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885KMT2A 1296/4885TSHR 1278/4885 |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CG | ALDH1A1 3409/4885KMT2A 2972/4885TSHR 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.